Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | KCNA3 | P22001 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | TNFRSF1A | P19438 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL662266 | 1.00 | ABCB1 (1.00) | ABCB1KCNA3MAPTNPSR1MAOB | |
| SCHEMBL25340278 | 0.89 | ABCB1 (0.80) | ABCB1KCNA3MAPTMAOBMAOA | |
| SCHEMBL662284 | 0.89 | ABCB1 (0.80) | ABCB1KCNA3MAPTMAOBMAOA | |
| SCHEMBL662283 | 0.89 | ABCB1 (0.80) | ABCB1KCNA3MAPTMAOBMAOA | |
| SCHEMBL25952345 | 0.89 | ABCB1 (0.80) | ABCB1KCNA3MAPTMAOBMAOA | |
| SCHEMBL25337768 | 0.88 | ABCB1 (0.78) | ABCB1MAPTMAOBCYP2C9MAOA | |
| SCHEMBL25952365 | 0.88 | ABCB1 (0.78) | ABCB1MAPTMAOBCYP2C9MAOA | |
| SCHEMBL25340515 | 0.86 | ABCB1 (0.76) | ABCB1KCNA3MAPTMAOBMAOA | |
| SCHEMBL25340711 | 0.86 | ABCB1 (0.76) | ABCB1KCNA3MAPTMAOBMAOA | |
| SCHEMBL25952337 | 0.86 | ABCB1 (0.76) | ABCB1KCNA3MAPTMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023177191-A1 | COMPOSITION FOR PREVENTING OR TREATING FIBROTIC DISEASES, COMPRISING DIMETHYLCHALCONE DERIVATIVE AS ACTIVE INGREDIENT | 서울대학교 산학협력단 | 2023-09-21 | — | — | WO | claimed |
| US-20230248665-A1 | COMPOSITION COMPRISING DIMETHYLCHALCONE DERIVATIVE FOR PREVENTION OR TREATMENT OF METABOLIC DISEASE | SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION (KR) | 2023-08-10 | — | — | US | claimed |
| US-20120046353-A1 | CLEISTOCALYX OPERCULATUS-DERIVED COMPOUNDS HAVING INHIBITORY ACTIVITIES AGAINST AVIAN AND SWINE INFLUENZA VIRUSES OR NOVEL INFLUENZA VIRUS | CHOONG ANG VACCINE LAB. (KR) | 2012-02-23 | — | — | US | claimed |
| WO-2012023660-A1 | ANTIVIRAL DRUG FOR AVIAN AND SWINE INFLUENZA AND NOVEL FLU, OBTAINED FROM CLEISTOCALYX OPERCULATUS | 주식회사 중앙백신연구소 (KR) | 2012-02-23 | — | — | WO | claimed |
| US-12428405-B2 | Chalcone-based chemotherapeutic compound for triple negative breast cancer | QATAR UNIVERSITY (QA) | 2025-09-30 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| US-20230365539-A1 | NOVEL CHALCONE-BASED CHEMOTHERAPEUTIC COMPOUND FOR TRIPLE NEGATIVE BREAST CANCER | QATAR UNIVERSITY (QA) | 2023-11-16 | — | — | US | disclosed |
| US-20230295103-A1 | AURONE DERIVATIVES AND USES THEREOF FOR CONTROLLING BACTERIA AND/OR FUNGI | ECOLE CENTRALE DE MARSEILLE (FR) | 2023-09-21 | — | — | US | disclosed |
| WO-2023177191-A1 | COMPOSITION FOR PREVENTING OR TREATING FIBROTIC DISEASES, COMPRISING DIMETHYLCHALCONE DERIVATIVE AS ACTIVE INGREDIENT | 서울대학교 산학협력단 | 2023-09-21 | — | — | WO | disclosed |
| WO-2023177191-A1 | COMPOSITION FOR PREVENTING OR TREATING FIBROTIC DISEASES, COMPRISING DIMETHYLCHALCONE DERIVATIVE AS ACTIVE INGREDIENT | 서울대학교 산학협력단 | 2023-09-21 | — | — | WO | disclosed |
| WO-2023177194-A1 | NOVEL DIMETHYLCHALCONE DERIVATIVES | 중앙대학교 산학협력단 | 2023-09-21 | — | — | WO | disclosed |
| WO-2023177194-A1 | NOVEL DIMETHYLCHALCONE DERIVATIVES | 중앙대학교 산학협력단 | 2023-09-21 | — | — | WO | disclosed |
| CN-101259118-A | Application of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethyl chalcone as PPAR gamma agonist | GUANGZHOU INST BIOMED & HEALTH (CN) | 2008-09-10 | — | — | CN | disclosed |
| US-20080166304-A1 | Inactivation of Microorganisms With Multidrug Resistance Inhibitors and Phenothiaziniums | THE GENERAL HOSPITAL CORPOARTION (US) | 2008-07-10 | — | — | US | disclosed |
| CN-100357264-C | Charles ketone oxime and its composition , preparation method and uses | SOUTH CHINA BOTAN GARDEN CHINE (CN) | 2007-12-26 | — | — | CN | disclosed |
| CN-1275923-C | Use of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethyl chalkone as reversing agent for resistance of multiple tumours drugs | UNIV EAST CHINA SCIENCE & TECH (CN) | 2006-09-20 | — | — | CN | disclosed |
| CN-1807405-A | Charles ketone oxime and its composition , preparation method and uses | SOUTH CHINA BOTAN GARDEN CHINE (CN) | 2006-07-26 | — | — | CN | disclosed |
| CN-1680248-A | Use of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethyl chalkone as reversing agent for resistance of multiple tumours drugs | HUADONG SCIENCE & ENGINEERING (CN) | 2005-10-12 | — | — | CN | disclosed |
| CN-1680248-A | Use of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethyl chalkone as reversing agent for resistance of multiple tumours drugs | HUADONG SCIENCE & ENGINEERING (CN) | 2005-10-12 | — | — | CN | disclosed |
| CN-1454895-A | Use of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethyl chalcone for preparing anticancer medicine | TUMOUR PREVENTION AND TREAT CT (CN) | 2003-11-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046353-A1 | CLEISTOCALYX OPERCULATUS-DERIVED COMPOUNDS HAVING INHIBITORY ACTIVITIES AGAINST AVIAN AND SWINE INFLUENZA VIRUSES OR NOVEL INFLUENZA VIRUS | PIGS, CLEC4M, ENGASE | ABCB1 4746/4885KCNA3 2228/4885MAPT 2192/4885 |
| US-12428405-B2 | Chalcone-based chemotherapeutic compound for triple negative breast cancer | BRCA1, TOP2B, TOP1 | ABCB1 8/4885KCNA3 4339/4885MAPT 1698/4885 |
| US-20230295103-A1 | AURONE DERIVATIVES AND USES THEREOF FOR CONTROLLING BACTERIA AND/OR FUNGI | AURKA, CYP51A1, AURKC | ABCB1 1680/4885KCNA3 1929/4885MAPT 2614/4885 |
| US-20230248665-A1 | COMPOSITION COMPRISING DIMETHYLCHALCONE DERIVATIVE FOR PREVENTION OR TREATMENT OF METABOLIC DISEASE | LIPC, PC, CYP27A1 | ABCB1 3180/4885KCNA3 4014/4885MAPT 1563/4885 |
| US-20230365539-A1 | NOVEL CHALCONE-BASED CHEMOTHERAPEUTIC COMPOUND FOR TRIPLE NEGATIVE BREAST CANCER | BRCA1, PGR, TOP2B | ABCB1 21/4885KCNA3 4277/4885MAPT 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.